title: Targeting human CD27 with an agonist antibody stimulates T-cell activation and antitumor immunity.
abstract: CD27 is an important co-stimulatory receptor of T cells that can potentially be exploited for immunotherapy. We developed a human IgG1 antibody that targets human CD27, and demonstrated its immunostimulatory and antineoplastic activity in various preclinical models. Currently, the antibody (1F5, CDX-1127) is being tested in patients affected by advanced malignancies.
authors.affiliation: Celldex Therapeutics, Inc.; Needham, MA USA.
authors.forename: Lawrence J
authors.initials: LJ
authors.lastname: Thomas
authors.affiliation: Celldex Therapeutics, Inc.; Phillipsburg, NJ USA.
authors.forename: Li-Zhen
authors.initials: LZ
authors.lastname: He
authors.affiliation: Celldex Therapeutics, Inc.; Needham, MA USA.
authors.forename: Henry
authors.initials: H
authors.lastname: Marsh
authors.affiliation: Celldex Therapeutics, Inc.; Phillipsburg, NJ USA.
authors.forename: Tibor
authors.initials: T
authors.lastname: Keler
keywords: CD27; Fc receptors; co-stimulation; immunotherapy; monoclonal antibody